EP3923903A1 - Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen - Google Patents

Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen

Info

Publication number
EP3923903A1
EP3923903A1 EP20705238.2A EP20705238A EP3923903A1 EP 3923903 A1 EP3923903 A1 EP 3923903A1 EP 20705238 A EP20705238 A EP 20705238A EP 3923903 A1 EP3923903 A1 EP 3923903A1
Authority
EP
European Patent Office
Prior art keywords
extract
composition
weight
stretch marks
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20705238.2A
Other languages
English (en)
French (fr)
Inventor
Jacques Peyrot
Jean-Marie Lefevre
Philippe Humbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Noreva Led
Original Assignee
Dermaconcept JMC SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67999711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3923903(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dermaconcept JMC SARL filed Critical Dermaconcept JMC SARL
Publication of EP3923903A1 publication Critical patent/EP3923903A1/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the present invention relates to a cosmetic and / or dermatological composition intended for preventing and / or treating the appearance of stretch marks on the skin.
  • Stretch marks are cutaneous streaks which appear in particular following an exaggerated distension of the skin, for example during weight gain, pregnancy, and / or a hormonal change, for example during puberty, and concern especially women.
  • Stretch marks can be localized on the front of the abdomen, on the breasts, thighs and hips.
  • stretch marks can arise under the effect of too rapid and sudden stretching of the skin: it is therefore the dermal tissue that is damaged, the target cell of these attacks being the fibroblast.
  • the first subject of the present invention is a composition
  • cosmetic and / or dermatological, in particular for topical application comprising:
  • the composition of the first object can be used, in particular in non-therapeutic use, for the prevention and / or treatment of stretch marks on the skin.
  • a second subject of the present invention is a composition for its application as a medicament for the prevention and / or treatment of stretch marks on the skin, comprising:
  • composition of the second object can be formulated for topical application.
  • composition according to the invention advantageously makes it possible to prevent and / or treat the appearance of stretch marks on the skin, while guaranteeing non-irritant properties for the skin.
  • the expression “prevention of stretch marks on the skin” is understood to mean an action making it possible to reduce, or even avoid, the formation of stretch marks in the context of a cosmetic and / or dermatological treatment, by application. of the composition, before and during an event known to cause the appearance of stretch marks.
  • the expression “treatment of stretch marks on the skin” is understood to mean an action making it possible to regress, or even to absorb, in the context of a cosmetic and / and dermatological treatment, in a visible and measurable manner, stretch marks already formed
  • composition used according to the invention can be applied topically to areas of the skin liable to form stretch marks, comprising stretch marks in the course of formation or even comprising stretch marks already formed. These areas are well known to those skilled in the art, and may correspond to the area of the stomach, hips, buttocks, thighs and / or breasts.
  • Hyaluronic acid is a natural glycosaminoglycan-type disaccharide-based polymer comprising D-glucuronic acid and N-acetylglucosamine units linked by glucosidic linkage.
  • It can be in free, hydrolyzed form, or else in the form of one of its salts, such as alkali metal and alkaline earth metal salts, for example sodium, potassium, calcium or magnesium hyaluronate.
  • salts such as alkali metal and alkaline earth metal salts, for example sodium, potassium, calcium or magnesium hyaluronate.
  • the hyaluronic acid usable in the invention is commercially available in various forms suitable according to the intended uses. It can be produced industrially in large quantities by extraction from animal tissues such as rooster ridges, or by bacterial fermentation, or else by biotechnological process from plant substances, for example wheat.
  • Hyaluronic acid or a salt thereof, by weight
  • molecular weight of at most 1000 kDa has the advantage of being able to cross the barrier of the stratum corneum and thus stimulate
  • CD44 receptors responsible for the neosynthesis of hyaluronic acid in the dermis are CD44 receptors responsible for the neosynthesis of hyaluronic acid in the dermis.
  • Hyaluronic acid or one of its salts, can have a weight
  • Hyaluronic acid or one of its salts, can also have a molecular weight of at most 800 kDa, and preferably at most 500 kDa.
  • hyaluronic acid can have a molecular weight ranging from 300 kDa to 500 kDa.
  • the studies carried out by the Applicant have shown that the choice of a hyaluronic acid meeting this condition allows an action in the epidermis, leading to an improvement in keratinocyte function, without directly affecting the dermis.
  • composition of the invention may comprise an effective amount of hyaluronic acid or one of its salts, the effective amount being that which is necessary to obtain the effects expected according to the invention.
  • composition of the invention may comprise from 0.01% to 5% by weight of hyaluronic acid or one of its salts, and of
  • hyaluronic acid or one of its salts preferably from 0.1% to 1% by weight of hyaluronic acid or one of its salts, relative to the total weight of the composition.
  • Ascorbic acid (or vitamin C) is an organic acid
  • L form i.e. L-ascorbic acid
  • natural products such as lemons, oranges, etc.
  • the ascorbic acid derivatives can be chosen from salts, such as in particular sodium ascorbate, magnesium or sodium ascorbylphosphate; esters, such as in particular acetic esters,
  • propionic or palmitic sugars, such as in particular glycosylated ascorbic acid; and one of their mixtures.
  • Ascorbic acid, or a derivative thereof is preferably in a stabilized form.
  • ascorbic acid, or one of its derivatives is in a substantially non-oxidizable form, and in particular a form which can be transported by a lipid.
  • stabilized ascorbic acid i.e. stable derivative of ascorbic acid
  • composition of the invention may comprise an effective amount of ascorbic acid or one of its derivatives, the effective amount being that which is necessary to obtain the effects expected according to the invention.
  • composition of the invention may comprise from 0.01% to 5% by weight of ascorbic acid or one of its derivatives, and of preferably 0.1% to 2% of ascorbic acid or a derivative thereof, relative to the total weight of the composition.
  • a peucedanum graveolens extract is an extract from a plant of the genus Peucedanum graveolens, a plant also known as dill.
  • the extract can be the plant as a whole, and / or one or more constituent elements of the plant such as a flower, a seed, a root, a rhizome, a stem, a fruit and / or a leaf.
  • the plant and / or the constituent elements of the plant can be prepared by grinding or chemical extraction well known to those skilled in the art.
  • graveolens can be an extract from the fruit of Peucedanum graveolens.
  • Such compounds may also be isolated from the plant by using extraction procedures well known to those skilled in the art, for example using organic solvents such as lower alcohols, Ci-C 8 alkyl polyols -C -C 8 alkyl ketones, Ci-C 8, alkyl ethers Ci-C 8 alkyl esters of Ci-C 8 of acetic acid and chloroform, and / or by using inorganic solvents such as water, inorganic acids such as hydrochloric acid, and inorganic bases such as sodium hydroxide.
  • the solvent for the extraction procedures is preferably an inorganic solvent, and particularly preferably water: the extract of Peucedanum graveolens can thus advantageously be an aqueous extract.
  • a particularly suitable extract of Peucedanum graveolens can be a product commercially available from BASF Beauty Care Solutions, under the reference Lys'Lastine, this product comprising an extract of Peucedanum graveolens in an amount of 5% to 10% by weight per relative to the total weight of said product.
  • composition of the invention may comprise an effective amount of extract of Peucedanum graveolens, the effective amount being that which is necessary to obtain the effects expected according to the invention.
  • composition of the invention may comprise from 0.001% to 2% by weight of extract of Peucedanum graveolens, and of
  • compositions in accordance with the present invention can be presented in the forms conventionally used for topical application, that is to say in the form of a gel, lotion, emulsion (in particular cream or milk), spot-on, serum (or essence), mask or ointment, containing the usual compatible and pharmaceutically acceptable excipients and carriers. They may also be in the form of patches, tulles or controlled-release dressings, or of wipes soaked in a composition according to the invention.
  • topical administration forms are prepared by techniques well known to those skilled in the art, and for example, in the case of a cream, by dispersing a fatty phase in an aqueous phase to obtain an oil emulsion. in water, or vice versa to prepare a water-in-oil emulsion.
  • composition according to the invention may comprise one or more usual excipients, suitable in particular for external topical administration, in particular dermatologically and / or cosmetologically acceptable excipients.
  • excipients suitable for the formulation are well known to those skilled in the art, and can be chosen, for example, from one or more of the compounds i to xv listed below:
  • antioxidant vitamins other than vitamin C or a derivative thereof, such as vitamin E, for example tocopherol acetate or tocotrienol; natural polyphenols;
  • buffers such as citric acid or a salt thereof; sodium hydroxide;
  • gelling agents and / or thickeners such as natural gums such as xanthan gum; synthetic polymers, for example
  • polyacrylamides of the Carbopol type crosslinked acrylate polymers and cellulose derivatives; sodium acrylate copolymers;
  • emulsifiers and co-emulsifiers such as arachidyl glucoside
  • cetearyl glucoside behenyl alcohol; cetearyl alcohol; cetostearyl alcohol; cetyl alcohol, steareth-2; steareth-21; isostearyl isostearate;
  • emollients and surfactants such as octyl dodecanol; isononyl isononanoate; capric / caprylic triglycerides; cetearyl octanoate; isopropyl myristate; cetearyl isononanoate; polyglyceryl 3-diisostearate; hydrogenated polyisobutene; cetyl palmitate; cetyl phosphate; vegetable oils such as macadamia oil; lecithin; glyceryl caprylate;
  • silicones such as dimethicone, cyclomethicone
  • humectants / moisturizers such as glycerin; butylene glycol; propylene glycol;
  • preservatives such as phenoxyethanol, dehydroacetic acid; benzoic acid; potassium sorbate; sodium benzoate; methyl or ethyl parahydroxybenzoates; chlorophenesin;
  • agents for protecting against ultraviolet rays such as hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from
  • benzophenone or a benzophenone derivative such as 2-hydroxy-4-methoxy-benzophenone; an ester of cinnamic acid, and more particularly octyl methoxycinnamate and ethyl-2-hexyl methoxycinnamate, or alternatively a cyano-b, b-diphenylacrylate such as octo-crylene, 4-methylbenzylidene camphor , and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane, t-butyl-methoxy dibenzoylmethane, and 4-methoxy-dibenzoylmethane; or such as pigments forming a UV screen; xi. exfoliating powders; fruit powders; or powders
  • mattifying agents such as methyl methacrylate copolymer; xii. neutralizing agents;
  • composition according to the invention can also comprise one or more usual additional active agents, suitable in particular for a
  • complementary active agents suitable for the formulation are well known to those skilled in the art, and can be, for example, anti-aging agents, soothing active ingredients, purifying active ingredients, moisturizing active ingredients, antimicrobial active ingredients, etc.
  • a third subject of the present invention is a use of an extract of Peucedanum graveolens, and more particularly a non-therapeutic use of an extract of Peucedanum graveolens, for the prevention and / or treatment of stretch marks on the skin.
  • said extract is used in topical application.
  • the active compounds are collated in Table 1 below:
  • the Lys'Lastine compound mainly comprises water and approximately 7.5% by weight of Peucedanum graveolens extract relative to the total weight of said compound.
  • the assets are diluted directly in a culture medium as described below.
  • a 2 mm diameter biopsy was taken from a red stretch mark from a 22-year-old man.
  • the classic explantation technique is used for the extraction of fibroblasts.
  • the explant is cultured in "Dulbecco's modified Eagle's medium” medium supplemented with 10% fetal calf serum (FCS), 40 mg / l of gentamicin and 2 mg / l of fungizone (DMEMc) at 37 ° C. , in a humid atmosphere and in the presence of 5% C0 2 .
  • FCS fetal calf serum
  • DMEMc fetal calf serum
  • DMEMc fetal calf serum
  • the culture medium is renewed twice a week. When the fibroblasts are in sufficient quantity, they are detached under the action of trypsin-EDTA, subcultured and amplified under the same culture conditions.
  • the equivalent dermis develop in a culture dish which consists of eight rectangular tanks. In each of them plunge two flexible blades, the lower parts of which are made up of grids on which the equivalent dermis clings during its polymerization. The equivalent dermis develops between two blades to result in a shape
  • the fibroblasts cultured in a monolayer and treated or not are trypsinized and then counted to bring the cell suspension to
  • a medium for manufacturing equivalent dermis is prepared by mixing:
  • the mixture is poured into the rectangular tanks of the GlasBox plus® . In a few minutes at 37 ° C, a gel is formed. The culture medium containing or not the active compounds is added and the isometric forces are measured for 24 hours.
  • test groups are as follows:
  • the amounts expressed in parentheses correspond to amounts by weight relative to the total weight of the culture medium.
  • the AUC and the Max are not significantly modified in the presence of 0.1% by weight of HA relative to the Control (decrease of approximately 4%).
  • the AUC and the Max are not significantly modified in the presence of 0.1% by weight of AA relative to the Control (decrease of approximately 1%).
  • the AUC and the Max are not significantly modified in the presence of 0.1% by weight of PG relative to the Control (decrease of approximately 4.5%).
  • the active compounds AA, AH or PG used alone have little or no effect on the contractile forces of red stretch mark fibroblasts.
  • Mixture C also has very little effect on the development of contractile forces.
  • Mixture I in accordance with the invention allows a very significant reduction in contractile forces and thus significantly limits or even prevents the rupture of stretch mark fibroblasts.
  • Mixture I has significant anti-stretch mark properties.
  • the amounts of the various constituents of the composition in Table 7 are expressed in% by weight relative to the total weight of the composition.
  • Hyaluronic acid is a hyaluronic acid of 450 kDa, marketed by the company Soliance, under the reference Primalhyal 450;
  • vitamin C is vitamin C stabilized in the form of ethyl-ascorbic acid, marketed by the company Safic-Alcan under the reference ET-VC
  • thickener and 17.5% by weight of humectant, relative to the total weight of said compound.
  • humectant emollient, thickener, emulsifier, preservative and buffer
  • emulsifier emulsifier
  • preservative emulsifier
  • buffer emulsifier
  • This gel can be easily applied in particular to the stomach, hips, buttocks, thighs and / or breasts.
  • this gel can be applied two to three times a day, preferably every 8 hours, and for at least 8 weeks, until satisfactory results are obtained.
  • the gel described above can be applied at least once or twice a day, for example in the morning and / or in the evening, for at least 12 weeks, and preferably for at least 24 weeks. .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
EP20705238.2A 2019-02-12 2020-01-23 Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen Pending EP3923903A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1901393A FR3092493A1 (fr) 2019-02-12 2019-02-12 Composition cosmétique et/ou dermatologique pour lutter contre les vergetures
PCT/FR2020/050092 WO2020165514A1 (fr) 2019-02-12 2020-01-23 Composition cosmétique et/ou dermatologique pour lutter contre les vergetures

Publications (1)

Publication Number Publication Date
EP3923903A1 true EP3923903A1 (de) 2021-12-22

Family

ID=67999711

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20705238.2A Pending EP3923903A1 (de) 2019-02-12 2020-01-23 Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen

Country Status (3)

Country Link
EP (1) EP3923903A1 (de)
FR (1) FR3092493A1 (de)
WO (1) WO2020165514A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113101245A (zh) * 2021-04-02 2021-07-13 广东袋鼠妈妈生物科技有限公司 一种具有修复妊娠纹功效的组合物和护理产品
WO2023235544A1 (en) * 2022-06-03 2023-12-07 Colgate-Palmolive Company Skin care compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784029B1 (fr) 1998-10-05 2001-01-05 Pharmascience Lab Methode de prevention et/ou de traitement cosmetique des vergetures de la peau et utilisation en dermatologie
WO2018065918A1 (en) * 2016-10-04 2018-04-12 Mary Kay Inc. Methods and compositions for treating striae distensae
CN108434080A (zh) * 2018-06-05 2018-08-24 深圳市旷逸生物科技有限公司 一种含表皮干细胞提取物的妊娠纹修复膏

Also Published As

Publication number Publication date
WO2020165514A1 (fr) 2020-08-20
FR3092493A1 (fr) 2020-08-14

Similar Documents

Publication Publication Date Title
EP1064931B1 (de) Kosmetisches Mittel enthaltend mindestens einen Hydroxystilben und Ascorbinsäure
EP2204162B1 (de) Verwendung von Monosacchariden und Zusammensetzung
EP3116599B1 (de) Kosmetische verwendung von swertia-marine
EP1001740B1 (de) Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese
LU93280B1 (fr) Composition cosmétique à base d'extraits d'Avena sativa, de Lens esculenta et de Tropaeolum majus
WO2019025725A1 (fr) Utilisation d'un extrait de péricarpe de nephelium lappaceum pour hydrater la peau et/ou les muqueuses
EP2691074A1 (de) Zusammensetzung auf der basis von camellia japonica und polygonum hydropiper zum schutz der haut
EP3923903A1 (de) Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen
FR2926220A1 (fr) Utilisation cosmetique d'un extrait de la plante pancratium maritimum comme agent cosmetique antioxydant et/ou inhibiteur de la melanogenese
EP2868313B1 (de) Verbindung von Vitamin C und Hyaluronsäure für die Behandlung von Hautalterungseffekten
EP3077061B1 (de) Zusammensetzung zur reduktion der hautalterung umfassend retinalaldehyd und einen extrakt von leontopodium alpinum
EP3085418B1 (de) Kosmetische zusammensetzungen, die oligomere der hyaluronsäure und dedifferenzierte, aus bougainvillea extrahierte pflanzliche zellen beinhalten, die ein safranextrakt einkapseln
WO2015118281A1 (fr) Composition pour lutter contre la chute des cheveux
EP2811977B1 (de) Verwendung eines apfelbaumblattextraktes in einer kosmetischen haut-straffungs zusammensetzung
EP1316301A1 (de) Kosmetisches oder dermatologisches Mittel enthaltend einen Retinoiden und/oder einen Carotenoiden und Acexamsäure
FR3021539A1 (fr) Composition cosmetique et/ou dermatologique comprenant un extrait vegetal et un activateur de genes
FR2818135A1 (fr) Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide
FR2828400A1 (fr) Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide
FR3099701A1 (fr) Nouvelle utilisation cosmétique d’une combinaison d’oenothéine-B et de quercétine-3-O-glucuronide
WO2021044013A1 (fr) Utilisation d'une composition comprenant un extrait de tulipa gesneriana
WO2003013464A1 (fr) Composition comprenant une association entre l'igf1 et l'acide ascorbique
WO2003013466A1 (fr) Composition comprenant une association de l'igf1 et au moins un isoflavonoide
FR2885049A1 (fr) Composition a base d'extraits de graines d'araucaria pour la protection de l'epiderme.
FR2968216A1 (fr) Nouvel actif antivergetures et compositions en contenant

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210902

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LABORATOIRES NOREVA-LED